Autopsy report · NCT03387085
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
Cause of deathNo reason given
“Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention”
Life of this trial
- Registered 3 months before it started.
- Ran for about 5 years 10 months before it stopped.
- 9 participants enrolled.
- Results were posted on the registry 7 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- ImmunityBio, Inc.
- Sponsor type
- Industry
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Aldoxorubicin HCl; N-803; ETBX-011; ETBX-051; ETBX-061; GI-4000
- Participants
- 9
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.